Epicardial Fat Tissue (EFT)EPIGRAPHNCT07604610
Epicardial Fat Tissue and Cardiometabolic Risk in Russian and Asian Populations
An observational study of Epicardial Fat Tissue (EFT) and Chronic Non-Communicable Diseases (NCDs), run by National Medical Research Center for Therapy and Preventive Medicine at 1 site in Russia.
Trial summary
Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling. Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- Epicardial Fat Tissue (EFT), Chronic Non-Communicable Diseases (NCDs), Visceral Obesity
- How many people
- 500 participants
- Where
- 1 siteRussia
- Study dates
- 4 May 2026to Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan
Who may be able to join
- Patients aged 50-70 years undergoing transthoracic echocardiography in inpatient or outpatient settings;
- Ability and willingness to provide informed consent.
Who cannot join
- Refusal to sign informed consent;
- Inability to perform transthoracic echocardiography or poor image quality;
- Severe psychiatric disorders.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
National Medical Research Center for Therapy and Preventive Medicine
Moscow
Olga Dzhioeva, MD, Associate Professor, +79166141821, odzhioeva@gnicpm.ru
About this study
Official title: Epicardial Fat Tissue Assessed by Echocardiography in Russian and Asian Populations: Association With Chronic Non-Communicable Diseases and Risk Factors
Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling.
According to the literature, increased EFT thickness is associated with a wide range of NCDs, disease severity, and prognosis.
The aim of this study is to investigate the associations between EFT thickness and clinical and anamnestic parameters, as well as to evaluate the prognostic value of this parameter in patients aged 50-70 years from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan.
Read the detailed description
The study is designed to:
- Assess physical examination findings, laboratory parameters, and comorbidities;
- Evaluate transthoracic echocardiography parameters;
- Analyze associations between EFT thickness and clinical and anamnestic characteristics;
- Determine threshold values of EFT thickness associated with structural and functional myocardial remodeling;
- Conduct follow-up via telephone to assess study endpoints;
- Evaluate the prognostic value of EFT thickness with respect to a composite endpoint.
- Keywords
- epicardial fat, echocardiography, cardiovascular risk, metabolic disorders, cohort study
- Medical subject headings
- Noncommunicable Diseases, Obesity, Abdominal, Metabolic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Observational cohort | Patients aged 50-70 years undergoing transthoracic echocardiography (TTE) in inpatient or outpatient |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite endpoint - all-cause mortality - hospitalizations - major adverse cardiovascular events (MACE)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start4 May 2026
- Primary completionMar 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epicardial Fat Tissue (EFT)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07604610
- Sponsor's protocol ID
- 02-02/26
- Acronym
- EPIGRAPH
- Status last verified
- May 2026
- First submitted
- 18 May 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epicardial Fat Tissue Assessed by Echocardiography in Russian and Asian Populations: Association With Chronic Non-Communicable Diseases and Risk Factors
- ClinicalTrials.gov ID
- NCT07604610
- Acronym / sponsor ID
- EPIGRAPH / 02-02/26
- Keywords
- epicardial fat, echocardiography, cardiovascular risk, metabolic disorders, cohort study
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- National Medical Research Center for Therapy and Preventive MedicineOther government
- Study start
- 4 May 2026 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling.
According to the literature, increased EFT thickness is associated with a wide range of NCDs, disease severity, and prognosis.
The aim of this study is to investigate the associations between EFT thickness and clinical and anamnestic parameters, as well as to evaluate the prognostic value of this parameter in patients aged 50-70 years from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan.
Detailed description
The study is designed to:
- Assess physical examination findings, laboratory parameters, and comorbidities;
- Evaluate transthoracic echocardiography parameters;
- Analyze associations between EFT thickness and clinical and anamnestic characteristics;
- Determine threshold values of EFT thickness associated with structural and functional myocardial remodeling;
- Conduct follow-up via telephone to assess study endpoints;
- Evaluate the prognostic value of EFT thickness with respect to a composite endpoint.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational cohort | – | –Patients aged 50-70 years undergoing transthoracic echocardiography (TTE) in inpatient or outpatient |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan
Key inclusion criteria (2 listed)
- Patients aged 50-70 years undergoing transthoracic echocardiography in inpatient or outpatient settings;
- Ability and willingness to provide informed consent.
Key exclusion criteria (3 listed)
- Refusal to sign informed consent;
- Inability to perform transthoracic echocardiography or poor image quality;
- Severe psychiatric disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Composite endpoint - all-cause mortality - hospitalizations - major adverse cardiovascular events (MACE)
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Epicardial Fat Tissue (EFT) and Chronic Non-Communicable Diseases (NCDs), run by National Medical Research Center for Therapy and Preventive Medicine at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olga Dzhioeva, MD, Associate Professor (+79166141821, odzhioeva@gnicpm.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite endpoint - all-cause mortality - hospitalizations - major adverse cardiovascular events (MACE) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.